Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2
Индукция мощного ответа нейтрализующих антител с помощью разработанных белковых наночастичных вакцин против SARS-CoV-2
2020-10-31
SCID: 54.1/p4exmcg6
Discuss with AI
SARS-CoV-2-RBD nanoparticle vaccineneutralizing antibody responsesreceptor-binding domainself-assembling protein nanoparticlesstructure-based vaccine design
Figures from the paper
Abstract (AI)
A safe, effective, and scalable vaccine is urgently needed to halt the ongoing SARS-CoV-2 pandemic. Here, we describe the structure-based design of self-assembling protein nanoparticle immunogens that elicit potent and protective antibody responses against SARS-CoV-2 in mice. The nanoparticle vaccines display 60 copies of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain (RBD) in a highly immunogenic array and induce neutralizing antibody titers roughly ten-fold higher than the prefusion-stabilized S ectodomain trimer despite a more than five-fold lower dose. Antibodies elicited by the nanoparticle immunogens target multiple distinct epitopes on the RBD, suggesting that they may not be easily susceptible to escape mutations, and exhibit a significantly lower binding:neutralizing ratio than convalescent human sera, which may minimize the risk of vaccine-associated enhanced respiratory disease. The high yield and stability of the protein components and assembled nanoparticles, especially compared to the SARS-CoV-2 prefusion-stabilized S trimer, suggest that manufacture of the nanoparticle vaccines will be highly scalable. These results highlight the utility of robust antigen display platforms for inducing potent neutralizing antibody responses and have launched cGMP manufacturing efforts to advance the lead RBD nanoparticle vaccine into the clinic.
Key Findings
1
High nanoparticle yield and stability indicated strong scalability for manufacturing, enabling cGMP efforts toward clinical development.
2
Nanoparticle-elicited antibodies targeted multiple distinct epitopes, potentially reducing susceptibility to viral escape mutations.
3
RBD nanoparticles induced neutralizing antibody titers 10-fold higher than prefusion-stabilized spike while using a 5-fold lower dose.
4
Structure-based self-assembling protein nanoparticles displaying 60 SARS-CoV-2 spike RBDs elicited potent protective antibody responses in mice.
5
The antibodies showed a lower binding-to-neutralizing ratio than convalescent human sera, potentially minimizing vaccine-associated enhanced respiratory disease risk.
Research Object
Self-assembling protein nanoparticle vaccines displaying SARS-CoV-2 spike receptor-binding domains (RBDs)
Research Subject
The immunogenicity, neutralizing and protective antibody responses, epitope targeting, and manufacturability of the RBD nanoparticle vaccines
Publication Details
Publication Date
2020-10-31
Journal
Publisher
ISSN
Cited by
530
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
A Novel Coronavirus from Patients with Pneumonia in China, 20192020
A pneumonia outbreak associated with a new coronavirus of probable bat origin2020
A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV2020
Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants2006
Cited by3
COVID-19 vaccine development: milestones, lessons and prospects2022
Two-Component Spike Nanoparticle Vaccine Protects Macaques from SARS-CoV-2 Infection2020
Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates2021